EMERSON SOARES BERNARDES

Resumo

Bachelor's at Farmácia from Universidade Federal de Ouro Preto (1998) and doctorate at Applied Imunology from Universidade de São Paulo (2004). Has experience in Medicine, acting on the following subjects: galectina-3, carboidratos, trypanosoma cruzi, carcinogênesis and macrophage. (Text obtained from the Currículo Lattes on October 8th 2021)


Possui graduação em Farmácia pela Universidade Federal de Ouro Preto (1998), mestrado e doutorado em Imunologia Básica e Aplicada pela Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo (2004), com período de Doutorado Sanduíche pela Universidade da California, Davis, USA. Realizou pós-doutoramento durante o período de 2004 a 2008 pela Faculdade de Medicina da USP-Ribeirão Preto. Trabalhou como pesquisador contratado pelo Instituto de Patologia e Imunologia Molecular da Universidade do Porto - IPATIMUP em Portugal no período de 2008 a 2011. Retornou ao Brasil como pesquisador visitante na Faculdade de Medicina da USP - São Paulo (2011-2012) e foi posteriormente contratado como pesquisador no Instituto do Câncer do Estado de São Paulo (2012-2013). Coordenou um projeto Jovem Pesquisador financiado pela FAPESP (2012-2016 - Desenvolvimento e Produção de Radiofármacos Emissores de Pósitrons com Aplicações Diagnósticas em Oncologia) e está integrado como pesquisador Colaborador no Instituto de Pesquisas Energéticas e Nucleares (IPEN). Tem atuado na área da Glicobiologia, com ênfase na participação de proteínas ligantes de carboidratos em processos inflamatórios e no Câncer. Atualmente é professor do Programa de Pós-Graduação do IPEN-USP Tecnologia Nuclear - Aplicações, tem experiência na área de Radiofarmácia, com ênfase no desenvolvimento de Radiofármacos inéditos para diagnóstico e terapia em Oncologia. (Texto extraído do Currículo Lattes em 08 out. 2021)

Projetos de Pesquisa
Unidades Organizacionais
Cargo

Resultados de Busca

Agora exibindo 1 - 2 de 2
  • Artigo IPEN-doc 29639
    Development of glycan‑targeted nanoparticles as a novel therapeutic opportunity for gastric cancer treatment
    2023 - SANTOS, SOFIA N. dos; GUSHIKEN JUNIOR, DINO S.; PEREIRA, JHONATAS P.M.; IADOCICCO, NATALIA M.; SILVA, ANDRE H.; NASCIMENTO, TATIELLE do; DIAS, LUIS A.P.; SILVA, FLAVIA R. de O.; RICCI-JUNIOR, EDUARDO; SANTOS-OLIVEIRA, RALPH; BERNARDES, EMERSON S.
    Chemotherapy resistance remains a major cause of therapeutic failure in gastric cancer. The combination of genetic material such as interference RNAs (iRNAs) to silence cancer-associated genes with chemotherapeutics has become a novel approach for cancer treatment. However, finding the right target genes and developing non-toxic, highly selective nanocarrier systems remains a challenge. Here we developed a novel sialyl-Tn-targeted polylactic acid—didodecyldimethylammonium bromide nanoparticle (PLA-DDAB) nanoparticles (NPs) loaded with dsRNA targeting ST6GalNac-I and/or galectin-3 genes. Using single photon emission computed tomography (SPECT), we have demonstrated that 99mtechnetium radiolabeled sialyl-Tn-targeted nanoparticles can reach the tumor site and downregulate ST6GalNAc-I and galectin-3 RNA expression levels when injected intravenously. Furthermore, using an in vivo gastric tumor model, these nanoparticles increased the effectiveness of 5-FU in reducing tumor growth. Our findings indicate that cancer-associated glycan-targeted NPs loaded with dsRNA targeting ST6GalNAc-I and/or galectin-3 in combination with standard chemotherapy, have the potential to become a novel therapeutic tool for gastric cancer.
  • Artigo IPEN-doc 25199
    Transcriptomic and functional analyses of the piRNA pathway in the Chagas disease vector Rhodnius prolixus
    2018 - BRITO, TARCISIO; JULIO, ALISON; BERNI, MATEUS; PONCIO, LISIANE de C.; BERNARDES, EMERSON S.; ARAUJO, HELENA; SAMMETH, MICHAEL; PANE, ATTILIO
    The piRNA pathway is a surveillance system that guarantees oogenesis and adult fertility in a range of animal species. The pathway is centered on PIWI clade Argonaute proteins and the associated small non-coding RNAs termed piRNAs. In this study, we set to investigate the evolutionary conservation of the piRNA pathway in the hemimetabolous insect Rhodnius prolixus. Our transcriptome profiling reveals that core components of the pathway are expressed during previtellogenic stages of oogenesis. Rhodnius' genome harbors four putative piwi orthologs. We show that Rp-piwi2, Rp-piwi3 and Rp-ago3, but not Rp-piwi1 transcripts are produced in the germline tissues and maternally deposited in the mature eggs. Consistent with a role in Rhodnius oogenesis, parental RNAi against the Rp-piwi2, Rp-piwi3 and Rp-ago3 results in severe egg laying and female adult fertility defects. Furthermore, we show that the reduction of the Rp-piwi2 levels by parental RNAi disrupts oogenesis by causing a dramatic loss of trophocytes, egg chamber degeneration and oogenesis arrest. Intriguingly, the putative Rp-Piwi2 protein features a polyglutamine tract at its N-terminal region, which is conserved in PIWI proteins encoded in the genome of other Triatomine species. Together with R. prolixus, these hematophagous insects are primary vectors of the Chagas disease. Thus, our data shed more light on the evolution of the piRNA pathway and provide a framework for the development of new control strategies for Chagas disease insect vectors.